Browsing Tag
IND
3 posts
Jupiter Neurosciences secures FDA green light for Phase 2a clinical trial of JOTROL in Parkinson’s disease
Find out how Jupiter Neurosciences’ FDA-approved JOTROL Phase 2a trial could reshape Parkinson’s treatment and redefine the biotech innovation race.
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.